The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
For the treatment of Superficial Femoral Artery
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3%
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Subscribe To Our Newsletter & Stay Updated
